BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025
• 2026

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 18
• 19
• 20
• 21
• 22
• 23
• 24
• 25
• 26
• 27
• 28
• 29
• 30

• 

  Drug Development

  Several Companies Tout Lung Cancer Breakthroughs at ESMO 2021

  Lung cancer is a particularly difficult cancer to treat, but several companies presented very promising data at this year’s European Society of Medical Oncology (ESMO) Congress 2021.

  September 20, 2021

   · 

  4 min read

   · 

  Mark Terry
• 

  Business

  Women-Led Jeito Capital Closes on $630 Million Life Sciences Investment Fund

  It is the largest venture capital fund in Europe focused on the life sciences.

  September 20, 2021

   · 

  2 min read

   · 

  Mark Terry
• 

  FDA

  Biogen and Samsung Bioepis Heat Up the Lucrative AMD Market with First Biosimilar Approval

  Three weeks after snagging approval in the UK, the U.S. FDA approved Samsung Bioepis and Biogen’s biosimilar drug. Byooviz is the first Lucentis copycat biologic to hit the market.

  September 20, 2021

   · 

  2 min read

   · 

  Kate Goodwin
• 

  Drug Development

  Pfizer-BioNTech Vaccine Found Safe and Effective in Kids Aged 5 to 11

  The Phase II/III trial showed a favorable safety profile and “robust” neutralizing antibody responses in children five to 11 years old who received two 10 µg doses of the vaccine at 21 days apart.

  September 20, 2021

   · 

  2 min read

   · 

  Vanessa Doctor, RN
• 

  Drug Development

  Hope Soars at ESMO 2021 for Breast Cancer Treatments

  Patients with different forms of breast cancer could soon have different treatment options following multiple presentations at the European Society of Medical Oncology meeting.

  September 20, 2021

   · 

  3 min read

   · 

  Alex Keown
• 

  Policy

  Protagonist’s PV Drug Placed on Hold After Mice Develop Tumors

  The company announced Friday that clinical studies have been placed on hold following the development of tumors in mice in a non-clinical study.

  September 20, 2021

   · 

  2 min read

   · 

  Heather McKenzie
• 

  Study: The Key to Weight Loss May Lie in Your Gut Microbiome

  Researchers from the Institute for Systems Biology observed 105 participants and found that failing or succeeding at shedding pounds is linked to one’s gut microbiome.

  September 20, 2021

   · 

  2 min read

   · 

  Vanessa Doctor, RN
• 

  Drug Development

  With New CEO at the Helm, Mirati Presents Positive Colorectal Cancer Data

  Mirati Therapeutics tapped David Meek, the former chief executive officer of Ipsen, as its new CEO. He replaces company founder Charles Baum.

  September 20, 2021

   · 

  2 min read

   · 

  Alex Keown
• 

  Business

  Investment in Biopharma is Reaching an Inflection Point

  During the past two years, fundraising and investment in biotechnology have reached record levels.

  September 20, 2021

   · 

  6 min read

   · 

  BioSpace Editorial Staff
• 

  Business

  New Appointees Strengthen Ventyx’s Team as Company Announces New Funding Round

  Sheila Gujrathi, M.D. will join the board of directors as executive chair, while Jörn Drappa, M.D., Ph.D. will serve as chief medical officer.

  September 20, 2021

   · 

  2 min read

   · 

  Ellen Bombela